BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34035335)

  • 1. Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype.
    Maeshima Y; Sakai T; Ogiya A; Takahashi Y; Miyagi Y; Kokubu Y; Osako T; Ito Y; Takahashi S; Ohno S; Ueno T
    Sci Rep; 2021 May; 11(1):10858. PubMed ID: 34035335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Boughey JC; Ballman KV; Hunt KK; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Le-Petross HT
    J Clin Oncol; 2015 Oct; 33(30):3386-93. PubMed ID: 25646192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
    Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
    Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
    Peppe A; Wilson R; Pope R; Downey K; Rusby J
    Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Fine Needle Aspiration Cytology on Sentinel Node Biopsy after Preoperative Chemotherapy for Core Needle Biopsy-Proven Metastatic Lymph Nodes.
    Nakamura R; Hayama S; Yoshimura S; Itami M; Araki A; Odaka A; Yamamoto N
    Acta Cytol; 2023; 67(4):378-387. PubMed ID: 36796341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical utility of assessment of the axilla in women with suspicious screen detected breast lesions in the post Z0011 era.
    Farshid G; Kollias J; Grantley Gill P
    Breast Cancer Res Treat; 2015 Jun; 151(2):347-55. PubMed ID: 25904216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
    Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
    Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
    Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
    Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study.
    Huang X; Shi Z; Mai J; Liu C; Liu C; Chen S; Lu H; Li Y; He B; Li J; Cun H; Han C; Chen X; Liang C; Liu Z
    Acad Radiol; 2023 Jul; 30(7):1257-1269. PubMed ID: 36280517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.
    van der Heiden-van der Loo M; de Munck L; Sonke GS; van Dalen T; van Diest PJ; van den Bongard HJ; Peeters PH; Rutgers EJ
    Eur J Cancer; 2015 May; 51(8):915-21. PubMed ID: 25857549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.
    İriağaç Y; Karaboyun K; Çavdar E; Avci O; Kurtoğlu Özçağlayan Tİ; Öznur M; Ozkan Gurdal S; Şeber ES
    Neoplasma; 2022 May; 69(3):741-746. PubMed ID: 35471979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
    El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
    Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.